Magic mushroom compound tested for cancer anxiety
NCT ID NCT05220046
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a single dose of psilocybin, the active ingredient in magic mushrooms, can reduce depression and anxiety in people with advanced pancreatic, biliary, or other gastrointestinal cancers. The study enrolls 24 adults aged 19-85 with stage IV or inoperable cancer who live near Omaha, NE. Participants receive the drug in a supportive setting, and researchers track changes in mood and distress over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Can music help children heal after domestic violence?
- Can a pill rouse the immune system against pancreatic cancer?
- Can a smart drug home in on Hard-to-Treat cancers?
- A new program aims to help teens thrive when a parent faces cancer
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?